Citations

Clear

4847 citation(s) found for "Tu, Eric".

Design considerations for C9orf72 disease prevention trials
Benatar, Michael , Staffaroni, Adam M. , Wuu, Joanne , McDermott, Michael P. , Quintana, Melanie , Swidler, Jean , Andersen, Gail, Huey, Edward D. , Turner, Martin R. , Macklin, Eric A. , Gendron, Tania, Onyike, Chiadi U. , Rosen, Howard J. , Heuer, Hilary W. , Grignon, Anne‐Laure , Dave, Kuldip D. , Balas, Calaneet, Satlin, Andrew , Dunn, Billy , Dacks, Penny A. , Boxer, Adam L. , Berry, James D , McMillan, Corey T , Gendron, Tania F , Onyike, Chiadi , Rosen, Howard J , Heuer, Hilary W , Grignon, Anne-Laure , Satlin, Andrew , Dacks, Penny , Boxer, Adam , Turner, Martin R , Wuu, Joanne , Andersen, Gail, Berry, James D. , McMillan, Corey T. , Gendron, Tania F. , Gleixner, Amanda M.

Mayo Clinic

Brain | August 3, 2025 | Volume: 148 | Issue: 11 | Pages: 3844-3855

10.1093/brain/awaf290 | PMID 40794569 Get It

Abstract The idea that it might be possible to prevent some forms of amyotrophic lateral sclerosis and frontotemporal dementia has finally come of age. The hexanucleotide repeat expansion in the C9orf72 gene accounts for ∼10% of all amyotrophic lateral sclerosis and 10%–15% of all frontotemporal dementia diagnoses, with the two clinical syndromes co-manifesting in a significant number of patients. As a result, clinically unaffected carriers of pathogenic C9orf72 repeat expansions are currently the largest identifiable population at significantly elevated risk for both amyotrophic lateral sclerosis and frontotemporal dementia, and in whom it might be possible to prevent the emergence of clinically manifest disease. Strategies for the design of disease prevention trials among clinically unaffected C9orf72 carriers have begun to emerge separately in the amyotrophic lateral sclerosis and frontotemporal dementia fields. However, recognition of the need to define neurodegenerative diseases based on biology underscores the need to consider all potential clinical manifestations of a C9orf72 repeat expansion together, rather than the traditional siloed approach of focusing on only amyotrophic lateral sclerosis or only frontotemporal dementia. Indeed, emerging clinical and biological markers that might be used to quantify pre-symptomatic disease progression and to predict the short-term risk of phenoconversion to clinically manifest disease are shared across the phenotypic spectrum. Given the anticipated progress in the development of therapeutic strategies to target the C9orf72 repeat expansion, and the enthusiasm for prevention trials among the unaffected C9orf72 repeat expansion carrier population, now is the time to begin work on the design of disease prevention trials. To this end, The Association for Frontotemporal Degeneration and The ALS Association supported a multi-stakeholder workshop (in Washington D.C., June 2024) to unify efforts to design a prevention trial for the population at elevated genetic risk for the phenotypic spectrum of C9orf72 disease. Here we describe recommendations emanating from this workshop for the selection of outcome measures, delineation of eligibility criteria, optimal use of biomarkers and digital health technologies, potential analytic frameworks and relevant regulatory considerations related to C9orf72 disease prevention trials. We also emphasize the importance of the amyotrophic lateral sclerosis and frontotemporal dementia communities working together in partnership with the C9orf72 repeat expansion carrier community, the regulatory authorities and the broader drug development community.
An immunohistochemical germinal center B-cell dark zone signature identifies Burkitt lymphoma and molecular high-grade B-cell lymphomas
Zhao, Xiaoxian , Balmaceda, Alexandra, Abiera, Via S, Garber, Desiree, Rosenblum, Lynne S. , Scott, David W. , Rimsza, Lisa M. , Hsi, Eric D.

Mayo Clinic

American Journal of Clinical Pathology | August 3, 2025 | Volume: 164 | Issue: 4 | Pages: 559-566

10.1093/ajcp/aqaf074 | PMID 40753450 Get It

Abstract Objective We hypothesized that a set of immunohistochemistry (IHC) stains could be used to distinguish Burkitt lymphoma (BL), the quintessential B-cell lymphoma with a germinal center B-cell (GCB) dark zone (DZ) expression signature, from diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). This might also be applicable to high-grade B-cell lymphomas (HGBCLs) with MYC and BCL2 rearrangements (double-hit lymphomas [DHLs]) and triple-hit lymphomas (THLs). Methods A 5-marker IHC algorithm was designed from gene lists that distinguish physiologic DZ from light zone GCBs. Results In training and validation cohorts, we distinguished BL from DLBCL, NOS with high sensitivity and specificity. Because DHLs/THLs are enriched for the gene expression DZ signature (DZsig), we evaluated 19 DHLs/THLs and 4 HGBCLs, NOS. Most (83%) cases were IHC DZ. The NanoString DLBCL90 assay was performed on 34 cases to correlate IHC DZ results with the molecular DZsig. The IHC DZ call was significantly associated with the DZsig (P = .0011). The sensitivity and specificity of IHC to recognize DZsig+ cases among DLBCL, NOS and DHLs with BCL2 rearrangements/THLs were 91% and 100%, respectively. Conclusions The IHC DZ algorithm can support a diagnosis of BL and identifies MYC-BCL2 DHLs/THLs with a molecular DZsig.
Prostate T2-Weighted Spin-Echo MRI With and Without Glucagon: A Paired Scan Quality Assessment
Hassanzadeh, Sara, Froemming, Adam T. , Takahashi, Naoki , Riederer, Stephen J. , Takahashi, Naoki , Borisch, Eric A. , Kawashima, Akira

Mayo Clinic

No container title available | August 1, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7217403/v1 Get It

Abstract Purpose To evaluate the effectiveness of subcutaneous glucagon in reducing motion artifact during prostate MRI through intraindividual comparison. Methods At our institution patients undergoing a clinical prostate MRI exam receive 1 mg of subcutaneous glucagon before scanning. From February 15, 2024 to February 11, 2025 33 such patients were recruited to undergo an additional, research exam without glucagon. All exams were acquired at 3T. An axial T2-weighted spin-echo series (T2-WI) was acquired within both exams. Evaluation of the T2-WI series was done by three experienced radiologists using the criteria of diagnostic quality (0–3 scale), PI-QUALv2 (0–3 sum), motion artifact (significant, visible, none), and reviewer preference (five-point relative scale). Due to differences in prescribed coverage, the scan times for the two T2-WI sequences were in general different for each subject. Results were stratified using the acquisition time ratio (Trel) between the glucagon vs. non-glucagon scans. Wilcoxon tests assessed score differences. Results Across all 33 subjects, no significant differences were found between glucagon and non-glucagon scans. However, the observed negative correlation between glucagon preference and Trel (p = 0.026) led to stratification into low-Trel (n = 16) and high-Trel (n = 17) groups. In the low-Trel group the glucagon scans provided significantly improved diagnostic quality (p = 0.048), PI-QUALv2 sum (p = 0.049), motion scores (p = 0.047), and reader preference (p = 0.042). Conclusion Subcutaneous glucagon provides improved image quality in prostate T2-WI MRI when scan duration remains within 1.25× of that of a non-glucagon T2-WI series. The benefit appears to decrease with longer scan times.
Surgical Management of Idiopathic Subglottic Stenosis During Pregnancy: A Multi‐Institutional Study
Awadallah, Andrew S. , Khalil, Yousuf H. , Bowen, Andrew J. , Ali, Hawa M. , Ring, Sydney , McCalla, Monet, Francis, David O. , Dailey, Seth H. , Edell, Eric S. , Ekbom, Dale C. , Bayan, Semirra L. , Ekbom, Dale , Bowen, Andrew Jay , Awadallah, Andrew , Francis, David O , Koster, Matthew J.

Mayo Clinic

The Laryngoscope | July 29, 2025 | Volume: 135 | Issue: 12 | Pages: 4767-4773

10.1002/lary.32464 | PMID 40726462 Get It

ABSTRACT Background Managing idiopathic subglottic stenosis (iSGS) during pregnancy presents distinct clinical challenges. As pregnancy is a naturally dyspneic state, the development of iSGS may exacerbate respiratory symptoms and compromise the airway—potentially impacting pregnancy and delivery decisions. This study characterizes surgical management strategies and outcomes in pregnant patients with symptomatic iSGS. Methods We conducted the largest known multi‐institutional retrospective review of pregnant patients who underwent endoscopic intervention for iSGS. Demographics, procedural details, anesthesia and medication use, and maternal and neonatal outcomes were analyzed. Results Twelve patients underwent 15 endoscopic procedures during pregnancy: 9 laser wedge excisions (8 CO 2 laser and 1 coblator) and 6 balloon dilations. Three additional procedures in different patients occurred postpartum (2–11 months after delivery). Higher‐risk pregnancies included two twin gestations, one patient with multiple surgeries during two different pregnancies, and two patients over age 35. Most interventions (87%) occurred in the second trimester. Fetal monitoring was performed preoperatively and postoperatively. Fentanyl and propofol were used in 88% and 94% of cases, respectively; rocuronium was the most common neuromuscular blocker (70%). One patient underwent balloon dilation via flexible bronchoscopy without anesthesia. Jet ventilation was used in 53% of cases, and Size C Kleinsasser laryngoscopes in 47%. Median procedure times were 75, 19, and 18 min for laser wedge excision, balloon dilation, and coblation, respectively. Most patients delivered full‐term with no surgical or postpartum complications. Conclusions Endoscopic intervention for iSGS during pregnancy appears safe and effective, even in high‐risk cases. These findings support individualized airway management and inform future practice. Level of Evidence 4.
Correction: Endoluminal radiofrequency ablation with stenting versus stenting alone in patients with malignant biliary obstruction: a meta-analysis of randomized trials
Ramai, Daryl , Maida, Marcello , Wang, Yichen , Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , DuBroff, Jason, Ko, Christopher , Morris, John D., Khashab, Mouen A., Wang, Yichen , Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , Marasco, Giovanni , Crinò, Stefano Francesco , Facciorusso, Antonio , Mangiavillano, Benedetto , Smith, Eric R. , Spadaccini, Marco , Previtera, Melissa J. , Bhandari, Peter , Marasco, Giovanni , Crinò, Stefano Francesco , Facciorusso, Antonio , Khashab, Mouen A.

Mayo Clinic

Endoscopy | July 28, 2025 | Volume: 57 | Issue: 09 | Pages: C11-C11

10.1055/a-2664-6391 | PMID 40720957 Get It

Breast Cancer Method of Detection: Frequently Asked Questions
Bahl, Manisha , Aminololama‐Shakeri, Shadi , Chen, L, Chikarmane, Sona A. , Dontchos, Brian N. , Lampen-Sachar, Katharine , Langman, Eun L. , Rosen, Eric L. , Rossi, Joanna , Ghate, Sujata V. , Dontchos, Brian N , Ojeda-Fournier, Haydee , Rossi, Joanna , Sharpe, Richard E. , Destounis, Stamatia V. , Eby, Peter R.

Mayo Clinic

Journal of Breast Imaging | July 26, 2025 | Volume: 7 | Issue: 6 | Pages: 718-728

10.1093/jbi/wbaf048 | PMID 41183368 Get It

Abstract The initial method of detection (MOD) refers to the first imaging examination, physical symptom, or clinical sign that prompts further investigation and ultimately leads to a new breast cancer diagnosis. The MOD is assigned at the patient level and falls into 1 of 3 categories: screening in asymptomatic patients, detection by patients or health care providers, or neither of the above. The MOD should be assigned prospectively by the radiologist when interpreting an examination with a final BI-RADS category of 4 or 5, before image-guided biopsy and breast cancer diagnosis. The MOD is not assigned to examinations classified as BI-RADS category 0, 1, 2, 3, or 6, nor is it assigned in the setting of an active breast cancer diagnosis. This Clinical Practice article addresses frequently asked questions and challenging clinical scenarios compiled by the American College of Radiology’s Screening and Emerging Technology Committee to guide consistent MOD assignment. For example, if a patient presents with a lump but is ultimately found to have a suspicious finding requiring biopsy in the contralateral breast, the MOD should reflect the reason for presentation, the patient-detected symptom (Pat), even if the cancer itself is asymptomatic. By increasing awareness of MOD and standardizing MOD reporting practices, radiologists can contribute to improved data collection. While MOD is not currently tracked in U.S. cancer registries, its systematic collection may offer valuable insights into screening effectiveness, technology performance, and disparities in cancer detection. Standardized MOD reporting has the potential to strengthen early detection efforts and improve outcomes across diverse clinical settings.
Super Learner Enhances Postoperative Complication Prediction in Colorectal Surgery
Violante, Tommaso , Novelli, Marco , Perry, William , Mathis, Kellie L. , Dozois, Eric J. , Violante, Tommaso , Perry, William R , Ferrari, Davide , Larson, David W.

Mayo Clinic

Annals of Surgery | July 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006847 | PMID 40698768 Get It

Objective: To determine if a Super Learner (SL) machine learning approach could improve the predictive accuracy of the American College of Surgeons Risk Calculator (ACS-RC) for postoperative complications in patients undergoing colorectal surgery. Summary of Background Data: Machine learning (ML) has shown significant potential to advance medical fields, including surgical risk prediction. Current tools, like the ACS-RC which uses logistic regression and extreme gradient boosting, are standard but may be enhanced by more advanced ML ensembles. Methods: This retrospective study analyzed colorectal surgery cases from the 2018-2022 ACS National Surgical Quality Improvement Program (NSQIP) database. An SL model, which combines multiple ML algorithms, was developed to predict fourteen postoperative outcomes. Its performance was compared against traditional logistic regression (LOG) and extreme gradient boosting (XGB) models. Key performance metrics included discrimination (AUROC, AUPRC) and calibration (Brier score, Hosmer-Lemeshow test). Results: The SL model demonstrated superior performance across all predicted complications when compared to both LOG and XGB. It showed superior discrimination for severe outcomes, achieving an AUROC greater than 0.94 for predicting mortality. The SL model was also more accurate in predicting infectious complications and length of stay, and its calibration metrics indicated a better overall fit and accuracy. Conclusions: The Super Learner model enhances the accuracy of postoperative risk prediction in colorectal surgery. Its superior performance suggests it is a promising tool for improving personalized patient counseling, aiding clinical decision-making, and optimizing resource allocation.
Executive Summary of the American Radium Society Appropriate Use Criteria for the Management of Peritoneal Carcinomatosis From Different Tumor Origins: Systematic Review and Guidelines
Carcinomatosis, Expert Panel Management of Peritoneal, Kennedy, Timothy J., Singh, Sareena , Abood, Gerard, Anker, Christopher J. , Akselrod, Dmitriy , Hallemeier, Christopher L. , Lee, Percy , Newman, Neil B., Sharma, Navesh , Williams, Vonetta M. , Russo, Suzanne , Akselrod, Dmitriy , Hallemeier, Christopher Leigh , Small, William , Russo, Suzanne , Carcinomatosis, Expert Panel Management of Peritoneal, Christenson, Eric, Jethwa, Krishan R. , Kim, Ed, Miller, Eric D. , Newman, Neil B., Selfridge, Jennifer Eva , Tchelebi, Leila T.

Mayo Clinic

Cancer Medicine | July 22, 2025 | Volume: 14 | Issue: 14 | Pages: No page available

10.1002/cam4.71043 | PMID 40693544 Get It

ABSTRACT Background Multimodality therapy incorporating a combination of cytoreductive surgery (CRS), intraperitoneal (IP) and systemic therapy continues to evolve for peritoneal carcinomatosis (PC) However, treatment and outcomes vary depending on tumor of origin. Aims To develop Appropriate Use Criteria (AUC) guidelines to facilitate treatment decision‐making for patients with PC based on available evidence. Materials and Methods The American Radium Society (ARS) multidisciplinary expert panel performed a comprehensive systematic review. Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well‐established modified Delphi consensus methodology. Results Treatment of PC is often treated with a combination of CRS and IP ± systemic chemotherapy but specific recommendations exist for different tumor types and outcomes vary. Discussion Treatment of PC is complex and varies depending on origin of primary tumor and extent of disease. These AUC assist in patient and treatment selection for different clinical scenarios. Conclusion A summary of recommendations is outlined to guide practitioners on the management of PC from different tumor origins.
The incidence and predictors of false-negative pancreatobiliary fluorescence in situ hybridization (PB-FISH) in biliary strictures: A prospective study
Aggarwal, Manik , Gores, Gregory J. , Law, Ryan , Martin, John A. , Petersen, Bret T. , Eaton, John E. , Roberts, Lewis R. , Gores, Gregory J. , Vargas, Eric J , Storm, Andrew C , Law, Ryan J, Roberts, Lewis R , Chandrasekhara, Vinay , Aggarwal, Manik , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu , Petersen, Bret T. , Ilyas, Sumera I. , Chandrasekhara, Vinay

Mayo Clinic

Hepatology Communications | July 21, 2025 | Volume: 9 | Issue: 8 | Pages: No page available

10.1097/hc9.0000000000000751 | PMID 40689505 Get It

Background: Fluorescence in situ hybridization (FISH) is recommended as part of multimodality sampling in the evaluation of biliary strictures, but can be false negative in 40%–50% cases. The aim of this study was to comprehensively assess predictors of false-negative FISH in patients with biliary strictures. Methods: Patients undergoing tissue sampling for biliary strictures from October 20 to February 22 were prospectively enrolled (NCT04572711). Procedural factors such as sampling techniques, order, and utilization of combination sampling were recorded. Results of an optimized pancreatobiliary FISH panel with locus-specific probes for 1q21, 7p12, 8q24, and 9p21 were reported per guidelines. Statistical analyses were performed using BlueSky Statistics v.10.3.1, R package v8.81. Results: Of 327 patients, 93 (28.5%) were diagnosed with malignancy. A false-negative pancreatobiliary fluorescence in situ hybridization (PB-FISH) was reported in 40 (43.1%) patients. A history of primary sclerosing cholangitis was associated with lower odds of having a false-negative PB-FISH (aOR=0.38, 95% CI=0.16–0.82, p=0.02), whereas a hilar stricture was associated with a significantly higher false-negative PB-FISH in those with cholangiocarcinoma (aOR=3.2 [1.4–7.9], p=0.009). Dilation of biliary strictures prior to brushing was not associated with a lower rate of false-negative PB-FISH. Conclusions: In this prospective study, hilar strictures were more likely to have false-negative PB-FISH. Dilation of strictures did not affect PB-FISH performance. These results can help guide PB-FISH interpretation.